Metoprol suc tab 50mg er
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Metoprolol Succinate Extended-Release 50mg Tablets: Pharmacokinetics, Bioequivalence, and Clinical Efficacy
Introduction to Metoprolol Succinate ER 50mg
Metoprolol succinate is a beta-blocker commonly prescribed for managing hypertension, angina, and heart failure. The extended-release (ER) formulation allows for once-daily dosing, providing consistent therapeutic effects over 24 hours. This article synthesizes research on the pharmacokinetics, bioequivalence, and clinical efficacy of metoprolol succinate ER 50mg tablets.
Pharmacokinetics of Metoprolol Succinate ER
Absorption and Tmax Variability
The pharmacokinetics (PK) of metoprolol succinate ER tablets have been extensively studied. A randomized, cross-over trial compared the PK profiles of brand-name metoprolol ER with two generic formulations. The study found that while the area under the concentration-time curve (AUC) and maximum concentration (Cmax) were similar across products, the time to maximum concentration (Tmax) varied significantly. The brand had a Tmax of 6.1 ± 3.6 hours, compared to 3.5 ± 4.9 hours for one generic and 9.6 ± 3.2 hours for another, indicating potential differences in drug release profiles.
Bioavailability and Release Rate
Another study focused on developing extended-release matrix tablets of metoprolol succinate to ensure near-constant drug release over 20 hours. The release rates for 50mg tablets were found to be 16.66%, 34.11%, 57.79%, and 87.30% at the 1st, 4th, 8th, and 20th hours, respectively. This controlled release is crucial for maintaining therapeutic levels and minimizing side effects.
Bioequivalence Studies
Fasting and Fed Conditions
Bioequivalence studies are essential to ensure that generic formulations provide the same therapeutic effects as the brand-name drug. A study involving healthy Chinese subjects under fasting and fed conditions demonstrated that the test metoprolol ER tablet was bioequivalent to the reference tablet (Betaloc ZOK). The 90% confidence intervals for AUC0-48h, AUC0-inf, and Cmax were within the acceptable range of 80-125%, confirming bioequivalence.
Therapeutic Equivalence
In another study, the therapeutic equivalence of brand-name and generic metoprolol ER tablets was evaluated in adults with hypertension. The study concluded that 24-hour blood pressure (BP) and heart rate (HR) measurements were similar across all formulations, further supporting the bioequivalence of these products.
Clinical Efficacy in Heart Failure
Mortality and Morbidity Benefits
Extended-release metoprolol succinate has shown significant benefits in managing chronic heart failure. The MERIT-HF trial, a large randomized, double-blind, placebo-controlled study, demonstrated that ER metoprolol succinate reduced the relative risk of all-cause mortality by 34% and sudden death by 41%. The drug was well tolerated, with a discontinuation rate due to adverse events similar to that of the placebo group.
Consistent Beta-1 Blockade
ER metoprolol succinate provides consistent beta-1 blockade over a 24-hour period, which is crucial for patients with heart failure. This consistent blockade helps in reducing mortality and morbidity, making it a valuable option for long-term management.
Conclusion
Metoprolol succinate ER 50mg tablets offer a reliable and effective option for managing hypertension and heart failure. Studies confirm their bioequivalence to brand-name formulations, ensuring similar therapeutic outcomes. The extended-release formulation provides consistent drug levels, enhancing patient compliance and clinical efficacy.
Sources and full results
Most relevant research papers on this topic